Quantum-Si Partners with SkyWater to Transform Proteomics with Next-Gen Proteus™ Platform

Quantum-Si and SkyWater Forge Path to Revolutionize Proteomics with Proteus™

Quantum-Si Incorporated, recognized as The Protein Sequencing Company™, amplifies its commitment to transforming proteomic research with an expanded collaboration with SkyWater Technology. This partnership, which builds on their previous work since 2021 with the first-generation Platinum® platform, aims to accelerate the development of Proteus™, Quantum-Si's next-generation platform set to redefine protein sequencing. The collaboration encompasses production support anticipated to begin in the second quarter of 2024, with SkyWater continuing to supply consumables for the existing Platinum Pro product. This strategic alliance promises to significantly enhance the capabilities of protein sequencing, offering unprecedented sample output, application flexibility, and automation.

The Proteus™ platform is designed to enable large-scale protein sequencing with enhanced accuracy, further solidifying Quantum-Si's position at the forefront of proteomic advancements. By integrating SkyWater's Technology as a Service (TaaS) model into their operations, Quantum-Si is poised to leverage streamlined manufacturing processes that adhere to the ISO 13485 Quality Standard for Medical Devices. This collaboration facilitates seamless communication between engineers and designers, ensuring tailored solutions that meet specific technological needs. The synergy between Quantum-Si's biotechnology expertise and SkyWater's manufacturing prowess is expected to yield significant breakthroughs in the proteomics field, ultimately benefiting both research and clinical applications.

Corporate leaders from both organizations express enthusiasm over this partnership. Ross Miller, SVP at SkyWater, emphasizes the transformative potential of their collaboration, which aims to drive innovations across various industries. Meanwhile, Jeff Hawkins, President and CEO of Quantum-Si, underscores the critical role SkyWater's manufacturing capabilities play in commercializing Proteus™, heralding a new era in protein sequencing that builds on the successes of the Platinum platform. As Quantum-Si continues to innovate, the collaboration with SkyWater stands as a testament to its dedication to advancing proteomics and enhancing research capabilities globally.

In addition to the collaboration with SkyWater, Quantum-Si recently announced a partnership with NVIDIA to further enhance the Proteus™ platform. This collaboration focuses on utilizing NVIDIA's advanced AI and accelerated computing technologies to improve data processing speeds, which is essential for managing the increased data volume generated by Proteus. The integration of NVIDIA's capabilities aims to provide deeper insights into the proteome, supporting advancements in research, drug discovery, and healthcare applications.

Overall, these strategic partnerships highlight Quantum-Si's commitment to revolutionizing the field of proteomics, harnessing cutting-edge technologies to advance both research and clinical applications while solidifying its leadership position in next-generation protein sequencing.